# A combination pricing rule so two-drug regimens are not priced as two monopolies

Source: https://onco.cc/ideas/idea-reg-combination-price-attribution/  
OnCo record `idea-reg-combination-price-attribution` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

When two expensive cancer drugs are combined, the price is often the sum of both even though the extra benefit is smaller. A rule for splitting the total value between them is needed.

## Summary

Combination regimens (checkpoint inhibitor plus targeted agent, ADC plus immunotherapy) frequently fail cost-effectiveness thresholds because each manufacturer prices for the full value, and competition law is cited as blocking joint negotiation. The UK's 2023 ABPI-NICE combination framework allows a backbone manufacturer to offer a rebate when its drug is used as part of a combination. The proposal is to generalise this: payers set a total price ceiling for the regimen based on its incremental benefit, a published attribution rule splits it between components, and competition authorities issue safe-harbour guidance for the resulting arrangements.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Under the framework, the proportion of combination regimens recommended by HTA bodies rises by at least a third, and total regimen prices fall relative to the sum of monotherapy prices.
- Rationale: The best new regimens are increasingly combinations of drugs from different companies; without an attribution mechanism, patients lose access to the most effective treatments because of a pricing coordination failure rather than any scientific limitation.
- Proposed test: Evaluate uptake and prices of combinations assessed under the UK framework over three years; adopt the framework in two other payers with competition-authority guidance and compare recommendation rates.
- Maturity: early-clinical
- Actor: payer

## Sources

- NICE combination treatments framework (page moved; nearest live section): https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/

## Connected records

- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-combination-price-attribution.json